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Abstract
Background: Drug-related death (DRD) figures, published by the national performance management framework, are
used to monitor the performance of Drug (and Alcohol) Action Teams (D[A]ATs) in England and Wales with respect to
reducing DRDs among drug abusers. To date, no investigation has been made into the types of death included in these
figures, the demographic and drug profile of those who died, nor the likelihood of individuals included in DRD figures
interacting with services designed to assist drug abusers. The aim of this work was to examine the characteristics of
deaths classified as drug-related and to explore their applicability to performance-monitor drug-related services.
Liverpool was chosen because it was reported by the national DRD monitoring system to have the highest number of
DRDs in 2004.
Methods: Information was retrieved from the Liverpool coroner's records and established monitoring systems on
individuals reported by the national performance monitoring system as a DRD between 1st January 2004 and 30th June
2005 (n = 70). Analyses assessed differences between those categorised by the national performance monitoring system
as 'drug abusers/dependents' and 'non-drug abusers/dependents' using χ2, Fisher's exact test and Mann-Whitney U.
Results: Non-drug abusers were significantly older (median age 53.59 vs. 38.23), had no recent contact with drug-related
agencies (cv. 31.6% of abusers who had treatment contact) and had different post mortem drug profiles than drug
abusers. A significantly greater proportion of non-drug abusers died from drug toxicity – predominantly through anti-
depressants, anti-psychotics and analgesics.
Conclusion: Our findings suggest that the national DRD performance monitoring system includes deaths of people who
are not drug abusers – individuals who are not the current focus of drug prevention, treatment or harm minimisation
services. This raises concerns regarding the applicability of these figures to performance monitor D(A)ATs. Furthermore,
using the more compact definitions used to monitor trends in DRDs across England, Wales and Europe fails to include
a proportion of deaths attributable to drug misuse – such as those attributable blood-borne viruses. Current definitions
used to monitor DRDs locally, nationally and across Europe fail to capture the true burden of drug-related mortality.
Background
Across Europe, problematic drug use (mainly opiate and
stimulant addiction) is associated with an elevated rate of
mortality – with an estimated 10–20% of deaths of young
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adults in European cities attributed to opioid use alone
[1]. While concerns over drug-related deaths (DRDs)
across Europe have prompted international monitoring
[2], the United Kingdom (UK) government has gone fur-
ther and implemented a DRD reduction target against
which local Drug [and Alcohol] Action Teams (D[A]ATs)
are performance-monitored [3]. What exactly constitutes
a DRD varies according to European [2] and national [4]
definitions. The choice of which definition is applied
determines the type of death included, and consequently,
the appropriateness of using such a measure for perform-
ance monitoring purposes.
Although the definition of a DRD adopted by the UK
national Drug Strategy is "a death where the underlying
cause is poisoning, drug abuse or drug dependence and where
any of the substances controlled under the Misuse of Drugs Act
(1971) are involved." (n = 16,088 DRDs, 1993–2004 [5]),
local DRD figures, used to monitor the performance of
D(A)ATs against local DRD reduction targets, are gener-
ated by the national programme on Substance Abuse
Deaths (np-SAD) using a wider definition which includes
all psychoactive substances, whether or not controlled
under the Misuse of Drugs Act (1971). Included within
the np-SAD definition are 'relevant deaths' where psycho-
active substances were implicated (with or without a post
mortem), where there is a history of drug abuse or where
controlled drugs were present at post mortem [6]. Despite
the role of these figures in assessing the performance of
local drug services, little is known about how those indi-
viduals recorded by np-SAD as DRDs have interacted with
substance misuse services or how their demographic and
behavioural profiles compare to problem drug users at
which drug treatment and prevention services are gener-
ally aimed and thus the relevancy of these figures in rela-
tion to deaths associated with drug abuse. Here, therefore,
we examine DRDs in the area of the UK with the highest
reported number in 2004 (Liverpool [7]) and explore how
many could be considered problematic drug users,
whether such individuals have previous or current contact
with health or judicial services for drug users and what fac-
tors contribute to their deaths. We discuss our findings in
terms of the consequences for DRD monitoring in the UK
and interpretation of DRD statistics currently compiled
across Europe.
Methods
In their Annual Report, np-SAD reported that 57 deaths
had occurred in Liverpool in 2004 [7]. In their Surveil-
lance Report, np-SAD reported that 28 DRD inquests were
completed in Liverpool during the first six months of
2005 [6]. Double counting of deaths was removed to
leave a total of 70 DRDs. Information about these 70 peo-
ple was retrieved from Liverpool DAAT and coroner
records. Existing monitoring systems were used to identify
whether deceased individuals had recently contacted local
drug-treatment services or drug-related criminal-justice
initiatives (matching used a person's initials, date of birth
and sex with the National Drug Treatment Monitoring
System for health records and Drug Arrest Referral [2003/
04] and its successor Drug Interventions Programme data-
base [2004/05] for criminal justice contact). np-SAD cate-
gorises DRDs into three groups ('drug abuser/dependent',
'non-drug abuser/dependent' and 'unknown drug abuser/
dependency') and the 70 DRDs were categorised accord-
ingly. According to np-SAD classifications, drug abuser
DRDs require a known history of drug abuse and any one
of four criteria to be met: 1) reported by the coroner as a
known illicit drug user; 2) prescribed substitute medica-
tion for drug dependence; 3) presence of a non-prescribed
illicit drug at post mortem, or 4) presence of any addi-
tional information on the coroner's report suggestive of a
history of drug abuse. Individuals are categorised as non-
drug abusers/dependents where none of these four criteria
were met and as 'unknown' drug abuser/dependent where
this information is not available [6]. Here we explore dif-
ferences between DRDs of drug abusers and non-drug
abusers in accordance with np-SAD definitions, using χ2,
Fisher's exact test and Mann-Whitney U.
Results
Half of DRDs were categorised by np-SAD as drug abusers
(Table 1). Deaths of non-drug abusers varied widely and
included, for example, one individual over 90 years old
with coronary heart disease who died of myocardial insuf-
ficiency with contributory carbamazepine toxicity. A
Mann-Whitney U analysis showed that non-drug abusers
were, on average, approximately 15 years older when they
died than drug abusers (median age 53.59 and 38.23
respectively; z = 3.942, P < 0.001). The proportion of
DRDs who had recently contacted local drug-treatment
services or drug-related criminal-justice initiatives was
small (31.6% and 18.4% respectively) and amongst non-
drug abusers was zero. Toxicological results differed sig-
nificantly between drug abusers and non-drug abusers.
Whilst heroin/morphine was detected during toxicologi-
cal investigations in half of those categorised as drug abus-
ers, it was present in only 14.3% of non-drug abusers (it is
not possible to differentiate between heroin and mor-
phine during post mortem – illicit or otherwise). A signif-
icantly greater proportion of non-drug abusers died from
toxicity-related deaths, the majority of which were related
to anti-depressants, anti-psychotics and opioid analgesics.
Discussion
DRD figures for England and Wales and across Europe are
reported in accordance with a similar and compact defini-
tion (see the UK Drug Strategy definition detailed in the
background section of this paper [5]). In relation to reduc-
ing DRDs, current UK policy dictates that a more expan-Substance Abuse Treatment, Prevention, and Policy 2007, 2:25 http://www.substanceabusepolicy.com/content/2/1/25
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sive definition (that of the np-SAD) is used by the
National Treatment Agency for Substance Misuse (NTA)
to monitor the performance of services locally [8]. Results
of this preliminary investigation suggest that there are
problems associated with using this wider definition of a
DRD for performance management purposes. Here we
show that this wider definition allows large numbers of
individuals who do not appear to be drug abusers to be
included in DRD figures. Illicit drug profiles for those clas-
sified by np-SAD as drug abusers and non-drug abusers
were significantly different with few toxicological investi-
gations of non-drug abusers identifying the presence of
drugs usually associated with problematic drug use (i.e.
heroin, cocaine/crack cocaine). A significantly greater pro-
portion of non-drug abusers actually died from drug tox-
icity – almost exclusively through psychoactive substances
not necessarily controlled under the Misuse of Drugs Act
(1971), for example anti-psychotics, anti-depressants and
opioid analgesics. These non-drug abusers are therefore
unlikely to be in contact with health or criminal justice
sectors for drug abuse and are also not the usual target of
drug prevention or harm minimisation services. Of
course, there is a need to address these deaths by tackling,
for instance, access to, and misuse and abuse of, pre-
scribed and off-the-shelf pharmaceutical products. How-
ever, this will require concerted action by a number of
agencies including primary care and mental health serv-
ices.
Alongside these non-drug abusers included by a wide def-
inition of a DRD, many deaths clearly related to problem-
atic drug use are currently being excluded. In particular,
the np-SAD, England and Wales and European definitions
exclude deaths due to bacterial and viral infections –
which are frequently transmitted via injecting practices –
despite these constituting a sizeable portion of drug-
related mortality. One recent study into the causes of
death of drug treatment clients in the North West of Eng-
land reported that 16% of all deaths were due to infec-
tions [9]. Nearly half of all injecting drug users in the UK
have been infected with hepatitis C [10], yet, under exist-
ing definitions, the estimated 4% who progress to severe,
potentially fatal cirrhosis as a result of their infection [11]
will be excluded from DRD figures in the UK and in
Europe. Consequently, in order to present a more accurate
picture of DRDs we suggest that the international defini-
tion of a DRD be modified to include those from blood-
borne factors. At the same time, the current policy of using
DRD figures to performance-monitor local drug partner-
ships requires greater consideration of whether those
agencies are positioned to provide interventions that
affect those individuals included in the definition.
Conclusion
The national drug-related deaths monitoring system,
whose figures are used to monitor the performance of
D(A)ATs across England and Wales, includes in its statis-
Table 1: Characteristics of drug-related deaths reported for Liverpool by drug abuse/dependent status (1st January 2004 to 30th June 
2005)
Variable Drug abuser/
dependent1
Not a drug abuser/
dependent
Unknown drug abuser/
dependent
Total P for the comparison 
between 'drug abuser/
dependent' and 'not a 
drug user/dependent'
n3 8 2 1 1 1 7 0
Male n (%) 24 (63.2) 13 (61.9) 8 (72.7) 45 (64.3) 0.924
Resident in Liverpool n (%) 27 (71.1) 18 (85.7) 10 (90.9) 55 (78.6) 0.338
Drugs known to have been 
detected in toxicological 
investigations n (%)2
Heroin/morphine 22 (57.9) 3 (14.3) 2 (18.2) 27 (38.6) 0.001
Methadone 12 (31.6) 1 (4.8) 0 13 (18.6) 0.022
Alcohol 15 (39.5) 11 (52.4) 5 (45.5) 31 (44.3) 0.339
Cocaine 16 (42.1) 0 3 (27.3) 19 (27.1) <0.001
Known history of alcohol abuse 
n (%)
10 (26.3) 7 (33.3) 5 (45.5) 22 (31.4) 0.569
Known drug treatment contact 
in 2003/04, 2004/05 or 2005/06 
n (%)
12 (31.6) 0 0 12 (17.1) 0.005
Known drug related criminal 
justice contact in 2003/04, 
2004/05 or 2005/06 n (%)3
7 (18.4) 0 0 7 (10.0) 0.043
Death from drug(s) toxicity n 
(%)4
19 (50.0) 19 (90.5) 7 (63.6) 45 (64.3) 0.002
Age at death, years median 
(inter quartile range)
38.23 (32.39 – 44.07) 53.59 (44.13 – 65.81) 41.15 (29.99 – 52.21) 42.36 (33.28 – 51.35) <0.001
All statistical comparisons used χ2 or Fisher's exact test except for 'age at death' where a Mann-Whitney U was used.
1Classification of deaths into 'drug abuser/dependent' categories is made by the national programme on Substance Abuse Deaths (np-SAD). 2The substance did not necessarily 
contribute to the death. 3Contacts with Arrest Referral Scheme in 2003/04 and Drug Interventions Programme in 2004/05 and 2005/06. 4Includes toxicity from prescribed 
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tics deaths of individuals who are not drug abusers. The
inclusion of deaths of non-drug abusers is consistent with
the aims of the national programme on Substance Abuse
Deaths, whose remit includes deaths from both licit and
illicit substances, yet prevention of these deaths demands
concerted action by agencies other than D(A)ATs whose
focus is primarily on problematic drug abuse (i.e. drug
addiction). Furthermore, excluded from current local,
national and European DRD definitions are deaths
known to be associated with drug abuse, such as those
caused by chronic hepatitis C infection. Using current
DRD definitions the true burden of drug-related mortality
within the UK and across Europe remains unknown.
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